Earnings next month may act as a catalyst, with Wall Street estimating a 6% YoY revenue growth driven by Keytruda demand. In another report released on September 16, Berenberg Bank also downgraded Merck & Co., Inc. (NYSE:MRK) to a Hold, bringing the price target down to $90 from $100. Keytruda is approved to treat 18 types of cancer, including of the skin, lung, breast and colon. It has been given to 2.9 million patients and helped former President Jimmy Carter extend his life by nearly a decade. Since arriving in 2014, Keytruda has generated $146 billion in sales for Merck. The drug accounts for nearly half of Merck’s revenue. Merck stock price shows marginal gains to $120.15 as biotech merger news fuels the sector. Technical support sits firmly near $118.